151 related articles for article (PubMed ID: 14742134)
1. Effects of renal diseases on the regulation and expression of renal and hepatic drug-metabolizing enzymes: a review.
Korashy HM; Elbekai RH; El-Kadi AO
Xenobiotica; 2004 Jan; 34(1):1-29. PubMed ID: 14742134
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiles of drug-metabolizing enzymes (DMEs) in rat liver during pregnancy and lactation.
He XJ; Yamauchi H; Suzuki K; Ueno M; Nakayama H; Doi K
Exp Mol Pathol; 2007 Dec; 83(3):428-34. PubMed ID: 16824515
[TBL] [Abstract][Full Text] [Related]
3. Regulation of drug-metabolizing enzymes by local and systemic liver injuries.
Guo Y; Hu B; Xie Y; Billiar TR; Sperry JL; Huang M; Xie W
Expert Opin Drug Metab Toxicol; 2016; 12(3):245-51. PubMed ID: 26751558
[TBL] [Abstract][Full Text] [Related]
4. The clinical role of genetic polymorphisms in drug-metabolizing enzymes.
Tomalik-Scharte D; Lazar A; Fuhr U; Kirchheiner J
Pharmacogenomics J; 2008 Feb; 8(1):4-15. PubMed ID: 17549068
[TBL] [Abstract][Full Text] [Related]
5. Effects of dioxane on cytochrome P450 enzymes in liver, kidney, lung and nasal mucosa of rat.
Nannelli A; De Rubertis A; Longo V; Gervasi PG
Arch Toxicol; 2005 Feb; 79(2):74-82. PubMed ID: 15490126
[TBL] [Abstract][Full Text] [Related]
6. Effects of renal failure on drug transport and metabolism.
Sun H; Frassetto L; Benet LZ
Pharmacol Ther; 2006 Jan; 109(1-2):1-11. PubMed ID: 16085315
[TBL] [Abstract][Full Text] [Related]
7. The influence of chronic renal failure on drug metabolism and transport.
Dreisbach AW
Clin Pharmacol Ther; 2009 Nov; 86(5):553-6. PubMed ID: 19776735
[TBL] [Abstract][Full Text] [Related]
8. Differential regulation of angiotensin II receptors during renal injury and compensatory hypertrophy in the rat.
Joly E; Nonclercq D; Caron N; Mertens J; Flamion B; Toubeau G; Kramp R; Bouby N
Clin Exp Pharmacol Physiol; 2005 Apr; 32(4):241-8. PubMed ID: 15810986
[TBL] [Abstract][Full Text] [Related]
9. In vivo effects of chronic contamination with depleted uranium on CYP3A and associated nuclear receptors PXR and CAR in the rat.
Souidi M; Gueguen Y; Linard C; Dudoignon N; Grison S; Baudelin C; Marquette C; Gourmelon P; Aigueperse J; Dublineau I
Toxicology; 2005 Oct; 214(1-2):113-22. PubMed ID: 16039771
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450 3A5 expression in the kidneys of patients with calcineurin inhibitor nephrotoxicity.
Joy MS; Hogan SL; Thompson BD; Finn WF; Nickeleit V
Nephrol Dial Transplant; 2007 Jul; 22(7):1963-8. PubMed ID: 17395652
[TBL] [Abstract][Full Text] [Related]
11. Modulation of hepatic and renal drug metabolizing enzyme activities in rats by subchronic administration of farnesol.
Horn TL; Long L; Cwik MJ; Morrissey RL; Kapetanovic IM; McCormick DL
Chem Biol Interact; 2005 Apr; 152(2-3):79-99. PubMed ID: 15840382
[TBL] [Abstract][Full Text] [Related]
12. Effect of breed upon cytochromes P450 and phase II enzyme expression in cattle liver.
Giantin M; Carletti M; Capolongo F; Pegolo S; Lopparelli RM; Gusson F; Nebbia C; Cantiello M; Martin P; Pineau T; Dacasto M
Drug Metab Dispos; 2008 May; 36(5):885-93. PubMed ID: 18268077
[TBL] [Abstract][Full Text] [Related]
13. Species differences in the response of liver drug-metabolizing enzymes to (S)-4-O-tolylsulfanyl-2-(4-trifluormethyl-phenoxy)-butyric acid (EMD 392949) in vivo and in vitro.
Richert L; Tuschl G; Viollon-Abadie C; Blanchard N; Bonet A; Heyd B; Halkic N; Wimmer E; Dolgos H; Mueller SO
Drug Metab Dispos; 2008 Apr; 36(4):702-14. PubMed ID: 18216275
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin II down-regulates the SR-BI HDL receptor in proximal tubular cells.
Wolf G; Wenzel U; Jablonski K; Brundert M; Rinninger F
Nephrol Dial Transplant; 2005 Jun; 20(6):1222-7. PubMed ID: 15894808
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of the organic cation transporter 1 of rat liver in obstructive cholestasis.
Denk GU; Soroka CJ; Mennone A; Koepsell H; Beuers U; Boyer JL
Hepatology; 2004 May; 39(5):1382-9. PubMed ID: 15122767
[TBL] [Abstract][Full Text] [Related]
16. Drug metabolizing enzymes-associated chemo resistance and strategies to overcome it.
Verma H; Singh Bahia M; Choudhary S; Kumar Singh P; Silakari O
Drug Metab Rev; 2019 May; 51(2):196-223. PubMed ID: 31203662
[TBL] [Abstract][Full Text] [Related]
17. Effects of liver diseases on drug-metabolizing enzymes: implications for drug fate alterations and nano-therapeutic openings.
Lu L; Shi J; Li Q; Peng X; Dong L; Li Y; Dai P; Wang Y; Guo E; Zhou F; Liu Z
Curr Med Chem; 2014; 21(22):2522-41. PubMed ID: 24358976
[TBL] [Abstract][Full Text] [Related]
18. Effect of chronic renal insufficiency on hepatic and renal udp-glucuronyltransferases in rats.
Yu C; Ritter JK; Krieg RJ; Rege B; Karnes TH; Sarkar MA
Drug Metab Dispos; 2006 Apr; 34(4):621-7. PubMed ID: 16415115
[TBL] [Abstract][Full Text] [Related]
19. D-Serine exposure resulted in gene expression changes indicative of activation of fibrogenic pathways and down-regulation of energy metabolism and oxidative stress response.
Soto A; DelRaso NJ; Schlager JJ; Chan VT
Toxicology; 2008 Jan; 243(1-2):177-92. PubMed ID: 18061331
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanism of phase I and phase II drug-metabolizing enzymes: implications for detoxification.
Iyanagi T
Int Rev Cytol; 2007; 260():35-112. PubMed ID: 17482904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
